Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):1–12. doi: 10.1016/j.clml.2017.11.008

Table 6.

The Myelofibrosis Secondary to PV and ET - Prognostic Model (MYSEC-PM)126

Clinical variable Points assigned
Hemoglobin <11 g/dL 2
Circulating blasts ≥3% 2
CALR-unmutated genotype 2
Platelets <150 × 109/L 1
Constitutional symptoms 1

Points total to be used along with patient age on published nomogram to identify risk category.